株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

プロテオミクス:技術と世界市場

Proteomics: Technologies and Global Markets

発行 BCC Research 商品コード 92659
出版日 ページ情報 英文 235 Pages
即納可能
価格
本日の銀行送金レート: 1USD=110.75円で換算しております。
Back to Top
プロテオミクス:技術と世界市場 Proteomics: Technologies and Global Markets
出版日: 2018年09月06日 ページ情報: 英文 235 Pages
担当者のコメント
BCC Research社は、3年に一度程度の頻度で、プロテオミクス市場のトレンドにフォーカスした調査レポートをリリースしており、9月に最新版が更新されました。バイオチップ別(PlanarArrays、LOC, BeadArrays)、疾患別(Cancer, Auto Immuno等)、製品区分別(Instrument & Consumable)に最新の技術トレンド、各社開発動向、市場予測をまとめております。
概要

世界のプロテオミクス市場は、2017年の79億米ドルから、2022年までに168億米ドルまで拡大すると見られています。市場は、2017年〜2022年のCAGR (複合年間成長率) で、16.2%の成長が予測されています。

当レポートでは、世界のプロテオミクス市場について調査分析し、市場概要、市場動向分析と予測、技術と応用、主要企業プロファイルなど、体系的な情報を提供しています。

第1章 イントロダクション

第2章 サマリーとハイライト

第3章 概要

  • プロテオミクス技術
  • 調査範囲
  • プロテオミクス市場
  • プロテオミクス産業の成長促進要因
    • プロテオミクス産業

第4章 プロテオミクス技術

  • イントロダクション
  • MSベースのプロテオミクス技術
    • 試料調整アッセイ
    • タギング/アフィニティ法
    • バイオマーカー識別のプロテオミクスの有用性
    • MS計器・消耗品
  • バイオチップベースのプロテオミクス技術
    • 多重化プロテオミクスシステム
    • プロテオゲノミクス
    • プロテオミクス技術の進歩

第5章 創薬開発におけるプロテオミクスの応用

  • 標的発見
  • リード特定
  • リード最適化
  • 前臨床研究

第6章 プロテオミクスの科学的イニシアチブ

第7章 プロテオミクスの臨床応用

  • がんの応用
    • 概要
    • 膀胱がん
    • 乳がん
    • 大腸がん
    • 胃がん
    • 腎臓がん
    • 肺がん
    • リンパ腫
    • 卵巣がん
    • 前立腺がん
    • 甲状腺がん
  • 感染症
  • 糖尿病
  • 神経疾患
    • アルツハイマー病
    • 統合失調症
  • 免疫疾患
    • HLA型
    • 自己免疫疾患
  • 循環器疾患
  • 妊娠高血圧腎症

第8章 プロテオミクス産業

  • 買収
  • 戦略的アライアンス
  • 質量分析産業
  • クロマトグラフィー産業
  • プロテオミクスベースの創薬開発産業
  • プロテオミクスバイオチップ産業
  • 抗体マイクロアレイ産業
  • 中国のバイオチップ産業
  • LOCプロテオミクス産業
  • 化学プロテオミクス産業
  • 抗体試薬産業
  • 多重タンパク質診断産業
  • 乾燥血液採取プロテオミクス産業
  • 単細胞プロテオミクス産業

第9章 プロテオミクス市場

  • プロテオミクス産業の成長促進要因
  • 世界のプロテオミクス市場

第10章 プロテオミクスの特許

  • タンパク質配列の特許

第11章 企業プロファイル

BCC Researchについて

図表

List of Tables

  • Summary Table: Global Proteomics Market, by End-User Industry, Through 2022
  • Table 1: Global Array versus LOC Biochips
  • Table 2: Scope of Report
  • Table 3: Global Proteomics Market by Platform, Through 2022
  • Table 4: Driving Forces in the Growth of the Proteomics Industry
  • Table 5: Biochip Industry Comparisons
  • Table 6: Mass Spectrometry Generalized Workflow Schematic
  • Table 7: Mass Spectrometer Platforms
  • Table 8: Biochip-Based Proteomics Technologies
  • Table 9: Planar-Based Versus Bead-Based Arrays
  • Table 10: Advantages of Multiplexing for Diagnostics
  • Table 11: Technical Advances in Proteomics
  • Table 12: Proteomic Applications in Drug Discovery and Development
  • Table 13: Large-Scale Proteomics Initiatives
  • Table 14: Some of the Cancer Markers used in Diagnosis and Treatment
  • Table 15: Strategies for Overcoming High-Abundance Proteins in Clinical Samples
  • Table 16: Estimated U.S. Incidence and Deaths for Selected Cancers, 2010, 2013 and 2018
  • Table 17: Status of Next-Generation Diagnostic Tests for Bladder Cancer
  • Table 18: Estimated Number of Annual Breast Cancer Treatment Decisions in the U.S., by Cancer Classification
  • Table 19: Breast Cancer MDx Technology Platforms
  • Table 20: Status of Next-Generation Diagnostic Tests for Gastric/Stomach Cancer
  • Table 21: Status of Next-Generation Diagnostic Tests for Kidney Cancer
  • Table 22: Five-Year Survival Rates for Non-Small Cell Lung Cancer, 2012-2017
  • Table 23: Status of Next-Generation Diagnostic Tests for Lung Cancer
  • Table 24: Status of Next-Generation Diagnostic Tests for Lymphomas
  • Table 25: Early Screening Tests for Ovarian Cancer
  • Table 26: Status of Next-Generation Diagnostics Tests for Ovarian Cancer
  • Table 27: Status of Next-Generation Diagnostics Tests for Pan-Cancer
  • Table 28: Status of Next-Generation Diagnostics Tests for Prostate Cancer
  • Table 29: Status of Next-Generation Diagnostics Tests for Thyroid Cancer
  • Table 30: Alzheimer's Disease Diagnostic Approaches
  • Table 31: Multiplex Autoimmune Testing Market
  • Table 32: Preeclampsia Diagnostic Tests
  • Table 33: Proteomics Industry Acquisitions, 2015-2018
  • Table 34: Strategic Alliances in the Proteomics Industry, 2015 -2018
  • Table 35: Mass Spectrometry Industry: Porter's Five Forces Analysis
  • Table 36: First-Tier Mass Spectrometry Companies
  • Table 37: Second-Tier Mass Spectrometry Companies
  • Table 38: Leading Manufacturers of High-Performance Liquid Chromatography Columns
  • Table 39: Leading Manufacturers of High-Performance Liquid Chromatography Columns in Japan
  • Table 40: Proteomics-Based Drug Discovery Industry
  • Table 41: Key Peptide Microarray Companies
  • Table 42: Leading High-Density Protein Array Companies
  • Table 43: Key Antibody Microarray Companies
  • Table 44: Leading Companies in China's Biochip Industry
  • Table 45: LOC Competitor Landscape
  • Table 46: Antibody Reagent Market, 2016
  • Table 47: Multiplex Protein In Vitro Diagnostics Companies
  • Table 48: Dried Blood Spot Proteomics Industry
  • Table 49: Single Cell Proteomics Industry
  • Table 50: Factors driving the growth of the Proteomics Industry
  • Table 51: Global Proteomic Market, by End-User Industry, Through 2022
  • Table 52: Global Proteomics Research Market, by Platform, Through 2022
  • Table 53: Global Proteomics Research Market, by Biochip Platform, Through 2022
  • Table 54: Global Proteomics Drug Discovery and Development Market, by Platform, Through 2022
  • Table 55: Global Proteomics Biochip Drug Discovery and Development Market, by Biochip Type, Through 2022
  • Table 56: Global Proteomics Diagnostic Market, by Platform, Through 2022
  • Table 57: Global Proteomics Diagnostic Market, by Biochip Type, Through 2022
  • Table 58: Global Proteomics Diagnostic Market, by Disease Type, Through 2022
  • Table 59: Status of Proteomics-Based Diagnostics for Diabetes, Neurological, Autoimmune, Infectious Disease, HLA Typing, and Cardiovascular Disease Applications
  • Table 60: Sepsis Diagnostics Industry
  • Table 61: Global Proteomics Cancer Diagnostic Market, by Indication, Through 2022
  • Table 62: Global Mass Spectrometry Market, by Product Type, Through 2022
  • Table 63: Global Mass Spectrometry Market, by End-User Industry, Through2022
  • Table 64: MRM-MS versus MALDI MS in Clinical Applications
  • Table 65: Status of MS Clinical Test Platforms
  • Table 66: Phosphoproteomics Platforms for Cancer Applications
  • Table 67: Global Mass Spectrometry Instrument Market for Proteomics, by Technique, Through 2022
  • Table 68: Global Mass Spectrometry Consumable Market, by Type, Through 2022
  • Table 69: Global Proteomics Biochip Market, by Platform, Through 2022
  • Table 70: Global Proteomics Arrays Market, by Type, Through 2022
  • Table 71: Global Proteomics Biochips Market, by End-User Industry, Through 2022
  • Table 72: Global Proteomics Array Market, by End-User Industry, Through 2022
  • Table 73: lobal Proteomics LOC Market, by End-User Industry, Through 2022
  • Table 74: Global Proteomics Market, by Region, Through 2022
  • Table 75: Global Proteomic Diagnostic Market, by Region, Through 2022
  • Table 76: Array-related Proteomics Patents by Region, 2015-2018
  • Table 77: LOC-related Proteomics Patents by Region, 2015-2018
  • Table 78: Mass Spectrometry-Related Proteomics Patents, by Region, 2015-2018
  • Table 79: Applications for Y2H and YChemH Proteomics Platforms
  • Table 80: Somalogic Proteomics Methods
  • Table 81: Universal Biosensors Diagnostic Pipeline

List of Figures

  • Summary Figure: Global Proteomics Market, by End-User Industry, 2016-2022
  • Figure 1: Proteomics Biochip and Array Formats
  • Figure 2: Chromatography Proteomics Workflow
目次
Product Code: BIO034E

Report Highlights:

The global market for proteomics should grow from $7.9 billion in 2017 to $16.8 billion by 2022 at a compound annual growth rate (CAGR) of 16.2% for the period of 2017-2022.

The global market for drug discovery and development/research as a segment of proteomics should grow from $5.3 billion in 2017 to $10.6 billion by 2022 at a CAGR of 14.9% for the period of 2017-2022.

The global market for applied/diagnostics as a segment of proteomics should grow from $2.7 billion in 2017 to $6.2 billion by 2022 at a CAGR of 16.2% for the period of 2017-2022.

Report Scope:

The study scope covers MS instruments, consumables, workflow products, planar arrays, bead arrays, and LOCs. It also covers the research, drug discovery and development, diagnostics, and applied end-user market segments. The main geographical markets-North America, Europe, Asia-Pacific, and Rest of the World (ROW)-are included.

The MS market is covered by instrument type, MS consumables, and product type and end-user markets. The biochip market is covered by biochip type and the end-user market for each type. The diagnostics market is covered in some detail, including by major platform (i.e., MS, biochips), by disease type and for cancer by indication. This report provides the current market sizes for these segments, as well as their forecasted growth through 2022.

Technology status and forces driving the market are discussed and analyzed. Factors that influence each market are also highlighted, including growth-driving forces, industry alliances and acquisitions, applications in diagnostics and drug discovery, customer needs, and competitive trends.

Key industry acquisitions and strategic alliances are given for the three-year period from 2015 through 2018.

This report also examines the main patent trends within the industry and profiles 108 proteomics companies.

Report Includes:

  • 20 data tables and 62 additional tables
  • An overview of the global proteomics market, which covers: technologies, platform and software markets, disease markets, biochip markets and end-use industry markets
  • Analyses of global market trends, with data from 2016 and 2017, and projections of CAGRs through 2022
  • Examination of market trends and opportunities that will impact the future market
  • A look at proteomics scientific initiatives, industry acquisitions and patents
  • Discussion of proteomic applications in drug discovery and development
  • Comprehensive company profiles across subsegments, such as protein chip providers, reagent providers, service providers, informatics and database providers, etc.
  • Company profiles of major players, including Abcodia Ltd., Bruker Corp., Digilab Inc., Glaxosmithkline Plc., & Luminex Corp.

Table of Contents

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing the Study
  • Intended Audience
  • Scope and Format
  • Methodology
  • Information Sources
  • Analyst's Credentials
  • BCC Custom Research
  • Related BCC Research Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview

  • Proteomic Technologies
  • Scope of Report
  • Proteomics Market
  • Driving Forces for Proteomics Industry Growth
  • The Proteomics Industry

Chapter 4 Proteomics Technologies

  • Introduction
  • MS-Based Proteomics Technologies
  • Sample Preparation Assays
  • Tagging/Affinity Methods
  • Utility of Proteomics to Identify Biomarkers
  • MS Instruments and Consumables
  • Biochip-Based Proteomics Technologies
  • Multiplex Proteomics Systems
  • Proteogenomics
  • Recent Advances in Proteomics Technologies

Chapter 5 Proteomics Applications in Drug Discovery and Development

  • Target Discovery
  • Lead Identification
  • Lead Optimization
  • Preclinical Studies

Chapter 6 Proteomics Scientific Initiatives

Chapter 7 Clinical Proteomics Applications

  • Applications in Cancer
  • Overview
  • Bladder Cancer
  • Breast Cancer
  • Colorectal Cancer
  • Gastric Cancer
  • Kidney Cancer
  • Lung Cancer
  • Lymphomas
  • Ovarian Cancer
  • Prostate Cancer
  • Thyroid Cancer
  • Infectious Diseases
  • Diabetes
  • Neurological Disorders
  • Alzheimer's Disease
  • Schizophrenia
  • Immune Diseases
  • HLA Typing
  • Autoimmune Disease
  • Cardiovascular Disease
  • Preeclampsia

Chapter 8 Proteomics Industry

  • Industry Acquisitions
  • Industry Strategic Alliances
  • Mass Spectrometry Industry
  • Chromatography Industry
  • Proteomics-Based Drug Discovery and Development Industry
  • Proteomics Biochip Industries
  • Peptide Microarray Industry
  • High-Density Protein Array Industry
  • Antibody Microarray Industry
  • China's Biochip Industry
  • LOC Proteomics Industry
  • Chemical Proteomics Industry
  • Antibody Reagent Industry
  • Multiplex Protein Diagnostics Industry
  • Dried Blood Spotting Proteomics Industry
  • Single Cell Proteomics Industry

Chapter 9 Proteomics Markets

  • Driving Forces of Proteomics Industry Growth
  • Global Proteomics Markets
  • Market Summary
  • Research Market
  • Drug Discovery and Development Market
  • Proteomics Diagnostic Market
  • Mass Spectrometry-Based Proteomics Market
  • Biochip-Based Proteomics Market
  • Proteomics Geographic Market

Chapter 10 Proteomics Patents

  • Protein Array Patents
  • Lab-on-a-Chip Patents
  • Mass Spectrometry Patents

Chapter 11 Company Profiles

  • ABCODIA LTD.
  • ABLYNX NV (ACQUIRED BY NOVO NORDISK)
  • ACTIVIOMICS LTD.
  • ACTIVX BIOSCIENCES INC.
  • ADVANCED PROTEOME THERAPEUTICS INC.
  • AGILENT TECHNOLOGIES INC.
  • APPLIED MICROARRAYS
  • APPLIED PROTEOMICS
  • ARRAYIT CORP.
  • ASTUTE MEDICAL INC.
  • AVACTA GROUP PLC.
  • AYOXXA BIOSYSTEMS GMBH
  • BIOCARTIS NV
  • BIODESIX INC.
  • BIOGNOSYS AG
  • BIOMERIEUX SA
  • BIOPROXIMITY LLC
  • BIO-RAD LABORATORIES INC.
  • BIO-TECHNE INC.
  • BRUKER CORP.
  • CAMBRIDGE PROTEIN ARRAYS LTD.
  • CAPRION BIOSCIENCES INC. (ACQUIRED BY GHO CAPITAL)
  • CAPROTEC BIOANALYTICS GMBH (ACQUIRED BY CHARLES RIVER LABORATORIES INTERNATIONAL INC.)
  • CARMENTA BIOSCIENCE INC. (ACQUIRED BY PROGENITY INC.)
  • CDI LABORATORIES INC.
  • CRELUX GMBH
  • CRESCENDO BIOSCIENCE (ACQUIRED BY MYRIAD GENETICS)
  • CRYSTALGENOMICS INC.
  • CYVEK INC. (ACQUIRED BY BIO-TECHNE)
  • DANAHER CORP.
  • DIASSESS
  • DIGILAB INC.
  • EPICYPHER INC.
  • EVOTEC AG
  • FLUIDIGM CORP.
  • GENERAL ELECTRIC CO.
  • GLAXOSMITHKLINE PLC.
  • GLOBAL DISCOVERY BIOSCIENCES
  • GL SCIENCES INC.
  • HEALTHTELL INC.
  • HYBRIGENICS SA
  • IMMUNOVIA AB
  • IMTAKT CORP.
  • INTEGRATED DIAGNOSTICS
  • INDI MOLECULAR
  • IRIS INTERNATIONAL INC. (ACQUIRED BY DANAHER CORP.)
  • LABCYTE INC.
  • LEAP TECHNOLOGIES INC. (ACQUIRED BY TRAJAN SCIENTIFIC AND MEDICAL)
  • LUMINEX CORP.
  • MERCK & CO. INC.
  • MERCK KGAA
  • MICROLYTIC (ACQUIRED BY ANATRACE)
  • MRM PROTEOMICS INC.
  • MOSAIQUES DIAGNOSTICS AND THERAPEUTICS AG
  • MYCARTIS
  • MYRIAD GENETICS INC.
  • NEWOMICS INC.
  • NIRMIDAS BIOTECH INC.
  • OLINK BIOSCIENCE
  • ONCOPLEX DIAGNOSTICS (ACQUIRED BY NANTOMICS)
  • OPKO HEALTH INC.
  • PERKINELMER INC.
  • PERSONALIZED CANCER THERAPY INC.
  • PFIZER INC.
  • PHENOMENEX INC.
  • PHYLOGICA LTD.
  • PRESSURE BIOSCIENCES INC.
  • PROMETIC LIFE SCIENCES INC.
  • PROTAGEN AG
  • PROTEA BIOSCIENCES INC.
  • PROTEOCYTE DIAGNOSTICS INC.
  • PROTEOGENIX
  • PROTEOME SCIENCES PLC.
  • PROTEOMICS INTERNATIONAL PTY LTD.
  • PROTEOVISTA LLC
  • PROVISTA DIAGNOSTICS INC.
  • QIAGEN NV
  • QUANSYS BIOSCIENCES
  • QUANTERIX INC.
  • QUEST DIAGNOSTICS INC.
  • REPLIGEN CORP.
  • RETROGENIX LTD.
  • SAMDI TECH INC.
  • SERA PROGNOSTICS
  • SHIMADZU CORP.
  • SHISEIDO COMPANY LTD.
  • SHOWA DENKO KK
  • SIGMA ALDRICH (ACQUIRED BY MERCK)
  • SINGULEX INC.
  • SISCAPA ASSAY TECHNOLOGIES INC.
  • SOMALOGIC INC.
  • SPHERE FLUIDICS LTD.
  • SPOTON CLINICAL DIAGNOSTICS LTD.
  • SQI DIAGNOSTICS
  • SYNAGEVA BIOPHARMA (ACQUIRED BY ALEXION PHARMACEUTICALS INC.)
  • T2 BIOSYSTEMS
  • THERANOSTICS HEALTH (ACQUIRED BY AVANT DIAGNOSTICS)
  • THERMO FISHER SCIENTIFIC INC.
  • THORNE DIAGNOSTICS INC.
  • TOSOH CORP.
  • UNIVERSAL BIOSENSORS LTD.
  • VERMILLION INC.
  • VG LIFE SCIENCES INC.
  • WATERS CORP.
  • XENCOR INC.
  • YMC CO. LTD.
  • ZEPHYRUS BIOSCIENCES INC. (ACQUIRED BY BIO-TECHNE CORP.)
Back to Top